NCT02664961: A reported trial by Tracon Pharmaceuticals Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02664961 |
|---|---|
| Title | A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2016 |
| Completion date | April 30, 2018 |
| Required reporting date | April 30, 2019, midnight |
| Actual reporting date | April 16, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |